SCHEMBL3012533

SCHEMBL3012533

COc1ccc(OC)c(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.48
MAPT P10636 4/20 0.48
RECQL P46063 2/20 0.48
USP2 O75604 2/20 0.48
HSD17B10 Q99714 1/20 0.48
ALDH1A1 P00352 5/20 0.44
TSHR P16473 3/20 0.44
LMNA P02545 3/20 0.44
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
HTT P42858 2/20 0.42
POLB P06746 2/20 0.42
HTR7 P34969 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 1/20 0.40
CHRM4 P08173 1/20 0.40
GBA1 P04062 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003853 0.93 MAPT (0.48) TP53MAPTRECQLUSP2HSD17B10
SCHEMBL3010012 0.92 TP53 (0.46) TP53MAPTRECQLUSP2HSD17B10
SCHEMBL3017730 0.91 MAPT (0.51) TP53MAPTRECQLUSP2HSD17B10
SCHEMBL3015005 0.91 MAPT (0.46) MAPTRECQLUSP2HSD17B10ALDH1A1
SCHEMBL3005437 0.90 TP53 (0.48) TP53MAPTRECQLUSP2HSD17B10
SCHEMBL3017934 0.90 MAPT (0.54) TP53MAPTRECQLUSP2HSD17B10
SCHEMBL3009159 0.90 MAPT (0.47) TP53MAPTRECQLUSP2HSD17B10
SCHEMBL3007163 0.89 MAPT (0.49) TP53MAPTRECQLUSP2HSD17B10
SCHEMBL3019561 0.89 ALDH1A1 (0.51) TP53MAPTRECQLUSP2ALDH1A1
SCHEMBL3008856 0.89 TSHR (0.50) TP53MAPTRECQLUSP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TP53 2880/4885MAPT 18/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.